Results 191 to 200 of about 720,196 (232)

Case Report: Challenges in the diagnosis and treatment of cardiac amyloidosis: a case misdiagnosed as dual cardiac amyloidosis. [PDF]

Front Cardiovasc Med
Ma M, Liu L, Liu X, Cai X, Yang W.
europepmc   +1 more source

Monitoring of Treatment Response in Light-chain Cardiac Amyloidosis-Does Echocardiography Have a Role? [PDF]

Echocardiography
Geenty P, Kwok F, Thomas L.
europepmc   +1 more source

Catheter ablation versus no ablation for atrial fibrillation in cardiac amyloidosis: a propensity-matched cohort study. [PDF]

Glob Cardiol Sci Pract
Fahed J, Hamza M, Naeem A, Rab AU, Khan MH, Sheffeh MA, Basit J, Assiri S, Alraies MC.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cardiac Amyloidosis

Critical Care Nurse, 2010
Amyloidosis is a clinical disorder caused by the extracellular deposition of misfolded, insoluble aggregated protein with a characteristic ss pleated sheet configuration that produces apple-green birefringence under polarized light when stained with Congo red dye.
Harit V, Desai, Wilbert S, Aronow, Stephen J, Peterson, William H, Frishman   +3 more
openaire   +4 more sources

Cardiac amyloidosis

Current Treatment Options in Cardiovascular Medicine, 1999
No definitive therapy is available for cardiac amyloidosis. Treatment with alkylating agents such as melphalan has improved survival. Patients who do not respond to melphalan have benefited from high-dose chemotherapy with cyclophosphamide followed by peripheral stem cell transplantation.
, Kashyap, , Hosenpud
openaire   +4 more sources

Cardiac amyloidosis

Expert Review of Cardiovascular Therapy, 2014
Amyloidosis is a condition characterized by the extracellular deposition of insoluble fibrillar protein in tissues and various organs including the heart. This review summarizes the clinical manifestations and diagnostic treatment approaches for cardiac amyloidosis.
Syed Wamique, Yusuf, Amirreza, Solhpour, Jose, Banchs, Juan C, Lopez-Mattei, Jean-Bernard, Durand, Cezar, Iliescu, Saamir A, Hassan, Muzaffar H, Qazilbash   +7 more
openaire   +2 more sources

The genetics of cardiac amyloidosis

Heart Failure Reviews, 2021
Heritable cardiac amyloidosis (CA) is an underrecognized cause of morbidity and mortality in the USA. It results from the accumulation of the misfolded protein transthyretin within the myocardium, resulting in amyloid transthyretin-associated cardiomyopathy (ATTR-CM). Over 150 different pathologic point mutations within the transthyretin gene have been
Scott Arno, Jennifer Cowger
openaire   +2 more sources

Echocardiography in cardiac amyloidosis

Heart Failure Reviews, 2015
Echocardiography is the most widely used noninvasive test in patients with heart failure or abnormal cardiac findings on examination. Patients with amyloidosis may have significant cardiac abnormalities, several of which are highly suggestive of the disease. This article reviews echocardiographic features found in cardiac amyloidosis.
Rodney H, Falk, C Cristina, Quarta
openaire   +2 more sources

Amyloidosis with cardiac involvement

Postgraduate Medical Journal, 2010
A previously well man in his 70s presented with a 2 month history of progressive dyspnoea, peripheral oedema, and purpuric rash affecting his legs. On examination, he was hypoxic, had ascites, bipedal oedema, and purpura on his legs. Bloods revealed a normocytic anaemia, renal failure, and hypoalbuminaemia.
Adrian Sze Wai, Yong, Shahid, Aziz
openaire   +2 more sources

Cardiac transthyretin amyloidosis

Heart, 2012
Cardiac amyloidosis of transthyretin fibril protein (ATTR) type is an infiltrative cardiomyopathy characterised by ventricular wall thickening and diastolic heart failure. Increased access to cardiovascular magnetic resonance imaging has led to a marked increase in referrals to our centre of Caucasian patients with wild-type ATTR (senile systemic ...
Jason N, Dungu, Lisa J, Anderson, Carol J, Whelan, Philip N, Hawkins   +3 more
openaire   +2 more sources